clofazimine has been researched along with Cryptosporidiosis in 10 studies
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
Cryptosporidiosis: Intestinal infection with organisms of the genus CRYPTOSPORIDIUM. It occurs in both animals and humans. Symptoms include severe DIARRHEA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the efficacy, pharmacokinetics (PK), and safety of clofazimine (CFZ) in patients living with human immunodeficiency virus (HIV) with cryptosporidiosis." | 9.41 | Clofazimine for Treatment of Cryptosporidiosis in Human Immunodeficiency Virus Infected Adults: An Experimental Medicine, Randomized, Double-blind, Placebo-controlled Phase 2a Trial. ( Arnold, SLM; Barrett, LK; Chen, CR; Conrad, TM; Douglas, E; Gordon, MA; Hebert, D; Henrion, M; Hermann, D; Hollingsworth, B; Houpt, E; Iroh Tam, P; Jere, KC; Lindblad, R; Love, MS; Makhaza, L; McNamara, CW; Nedi, W; Nyirenda, J; Operario, DJ; Phulusa, J; Quinnan, GV; Sawyer, LA; Thole, H; Toto, N; Van Voorhis, WC; Winter, A, 2021) |
| " Primary endpoints include reduction in the number of Cryptosporidium shed in stools over a 5-day period and compared to placebo recipients and the PK of CFZ in plasma assessed by area under the curve, peak plasma concentration, and half-life (T ½) determined after the last dose." | 6.87 | Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial. ( Gordon, MA; Hermann, D; Iroh Tam, PY; Nachipo, P; Quinnan, G; Van Voorhis, WC, 2018) |
| " The CRYPTOFAZ trial, previously published, was conducted in Malawi to evaluate the efficacy of clofazimine in response to an unmet need for drugs to treat cryptosporidiosis in HIV populations." | 5.69 | Examination of ELISA against PCR for assessing treatment efficacy against Cryptosporidium in a clinical trial context. ( Chen, C; Conrad, T; Hebert, D; Henrion, MYR; Houpt, ER; Iroh Tam, PY; Jere, KC; Msakwiza, M; Nedi, W; Nyasulu, V; Nyirenda, JT; Operario, DJ; Phulusa, J; Sawyer, LA; Thole, H; Toto, N; Van Voorhis, WC; Winter, A, 2023) |
| "Clofazimine has a long history of use and has demonstrated a good safety profile for a disease that requires chronic dosing for a period of time ranging 3-36 months." | 5.46 | A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis. ( Beasley, FC; Chatterjee, AK; Huston, CD; Jumani, RS; Love, MS; McNamara, CW; Schultz, PG; Wright, TM, 2017) |
| "We evaluated the efficacy, pharmacokinetics (PK), and safety of clofazimine (CFZ) in patients living with human immunodeficiency virus (HIV) with cryptosporidiosis." | 5.41 | Clofazimine for Treatment of Cryptosporidiosis in Human Immunodeficiency Virus Infected Adults: An Experimental Medicine, Randomized, Double-blind, Placebo-controlled Phase 2a Trial. ( Arnold, SLM; Barrett, LK; Chen, CR; Conrad, TM; Douglas, E; Gordon, MA; Hebert, D; Henrion, M; Hermann, D; Hollingsworth, B; Houpt, E; Iroh Tam, P; Jere, KC; Lindblad, R; Love, MS; Makhaza, L; McNamara, CW; Nedi, W; Nyirenda, J; Operario, DJ; Phulusa, J; Quinnan, GV; Sawyer, LA; Thole, H; Toto, N; Van Voorhis, WC; Winter, A, 2021) |
| " The pneumatosis resolved upon treatment of the cryptosporidiosis with paromomycin and clofazimine." | 3.69 | Pneumatosis cystoides intestinalis in AIDS-associated cryptosporidiosis. More than an incidental finding? ( Brown, WR; Samson, VE, 1996) |
| " The following areas were emphasized at the conference: multiresistant gram-positive bacteremias in patients with serious underlying infections, azithromycin's effectiveness against acute community-acquired pneumonia, results of clarithromycin plus ethambutol in HIV-infected patients with MAC bacteremia, duodenal ulcers associated with Helicobacter pylori infections, and use of roxithromycin against AIDS-related cryptosporidium diarrhea." | 3.69 | Macrolides, azalides, and streptogrammins. ( Prescott, LM, 1996) |
| " Results of a Taiwanese trial of thymosin-alpha indicate that it did not help treat Hepatitis B in a statistically significant way." | 3.69 | Pot shots. ( , 1996) |
| " Primary endpoints include reduction in the number of Cryptosporidium shed in stools over a 5-day period and compared to placebo recipients and the PK of CFZ in plasma assessed by area under the curve, peak plasma concentration, and half-life (T ½) determined after the last dose." | 2.87 | Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial. ( Gordon, MA; Hermann, D; Iroh Tam, PY; Nachipo, P; Quinnan, G; Van Voorhis, WC, 2018) |
| "Clofazimine has a long history of use and has demonstrated a good safety profile for a disease that requires chronic dosing for a period of time ranging 3-36 months." | 1.46 | A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis. ( Beasley, FC; Chatterjee, AK; Huston, CD; Jumani, RS; Love, MS; McNamara, CW; Schultz, PG; Wright, TM, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nyirenda, JT | 1 |
| Henrion, MYR | 1 |
| Nyasulu, V | 1 |
| Msakwiza, M | 1 |
| Nedi, W | 2 |
| Thole, H | 2 |
| Phulusa, J | 2 |
| Toto, N | 2 |
| Jere, KC | 2 |
| Winter, A | 2 |
| Sawyer, LA | 2 |
| Conrad, T | 1 |
| Hebert, D | 2 |
| Chen, C | 1 |
| Van Voorhis, WC | 3 |
| Houpt, ER | 1 |
| Iroh Tam, PY | 2 |
| Operario, DJ | 2 |
| Iroh Tam, P | 1 |
| Arnold, SLM | 1 |
| Barrett, LK | 1 |
| Chen, CR | 1 |
| Conrad, TM | 1 |
| Douglas, E | 1 |
| Gordon, MA | 2 |
| Henrion, M | 1 |
| Hermann, D | 2 |
| Hollingsworth, B | 1 |
| Houpt, E | 1 |
| Lindblad, R | 1 |
| Love, MS | 2 |
| Makhaza, L | 1 |
| McNamara, CW | 2 |
| Nyirenda, J | 1 |
| Quinnan, GV | 1 |
| Huston, CD | 2 |
| Zhang, Y | 1 |
| Feng, J | 1 |
| McManus, SA | 1 |
| Lu, HD | 1 |
| Ristroph, KD | 1 |
| Cho, EJ | 1 |
| Dobrijevic, EL | 1 |
| Chan, HK | 1 |
| Prud'homme, RK | 1 |
| Chavez, MA | 1 |
| White, AC | 1 |
| Nachipo, P | 1 |
| Quinnan, G | 1 |
| Beasley, FC | 1 |
| Jumani, RS | 1 |
| Wright, TM | 1 |
| Chatterjee, AK | 1 |
| Schultz, PG | 1 |
| Samson, VE | 1 |
| Brown, WR | 1 |
| Prescott, LM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of Clofazimine (CFZ) in Cryptosporidiosis[NCT03341767] | Phase 2 | 33 participants (Actual) | Interventional | 2017-12-14 | Terminated (stopped due to Insufficient accrual rate) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for clofazimine and Cryptosporidiosis
| Article | Year |
|---|---|
Novel treatment strategies and drugs in development for cryptosporidiosis.
Topics: Animals; Antiprotozoal Agents; Clofazimine; Cryptosporidiosis; Diarrhea; Drug Development; Global He | 2018 |
3 trials available for clofazimine and Cryptosporidiosis
| Article | Year |
|---|---|
Examination of ELISA against PCR for assessing treatment efficacy against Cryptosporidium in a clinical trial context.
Topics: Animals; Clofazimine; Cryptosporidiosis; Cryptosporidium; Enterotoxigenic Escherichia coli; Enzyme-L | 2023 |
Clofazimine for Treatment of Cryptosporidiosis in Human Immunodeficiency Virus Infected Adults: An Experimental Medicine, Randomized, Double-blind, Placebo-controlled Phase 2a Trial.
Topics: Adult; Biomedical Research; Clofazimine; Cryptosporidiosis; Cryptosporidium; Diarrhea; HIV; HIV Infe | 2021 |
Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antiprotozoal | 2018 |
6 other studies available for clofazimine and Cryptosporidiosis
| Article | Year |
|---|---|
The Clofazimine for Treatment of Cryptosporidiosis in HIV-Infected Adults (CRYPTOFAZ) and Lessons Learned for Anticryptosporidial Drug Development.
Topics: Adult; Clofazimine; Cryptosporidiosis; Diarrhea; Drug Development; HIV Infections; Humans | 2021 |
Design and Solidification of Fast-Releasing Clofazimine Nanoparticles for Treatment of Cryptosporidiosis.
Topics: Antiparasitic Agents; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Clofazimine; Cr | 2017 |
A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis.
Topics: Animals; Antiprotozoal Agents; Automation, Laboratory; Cell Line; Clofazimine; Cryptosporidiosis; Cr | 2017 |
Pneumatosis cystoides intestinalis in AIDS-associated cryptosporidiosis. More than an incidental finding?
Topics: Adult; AIDS-Related Opportunistic Infections; Clofazimine; Cryptosporidiosis; Humans; Male; Paromomy | 1996 |
Macrolides, azalides, and streptogrammins.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; B | 1996 |
Pot shots.
Topics: Acetylcysteine; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antitubercula | 1996 |